Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole

M. S. Frank, L. J. Brandt, L. H. Bernstein

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Studies have shown metronidazole to be useful in the treatment of colon Crohn's disease, especially for perineal complications. It appears to equal sulfasalazine in effectiveness and to offer hope to patients who fail to respond to that drug. However, exacerbation of perineal disease is to be expected on discontinuation of therapy. The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive. Although no studies exist showing the drug to be mutagenic, teratogenic, or carcinogenic in humans, animal and laboratory tests raise concern of this possibility. For this reason, metronidazole therapy should be stopped in two to six months if ineffective and stopped periodically when disease is controlled to see if it can be discontinued.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalPostgraduate Medicine
Issue number6
StatePublished - Jan 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole'. Together they form a unique fingerprint.

Cite this